Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia

Blood

Volumn 127, Issue 4, 2016, Pages 464-472

  Tutwiler, Valerie ^a,b   Madeeva, Daria ^b   Ahn, Hyun Sook ^b   Andrianova, Izabella ^c   Hayes, Vincent ^b   Zheng, X Long ^d   Cines, Douglas B ^e   McKenzie, Steven E ^f   Poncz, Mortimer ^b,e   Rauova, Lubica ^b,e  

^a DREXEL UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FC RECEPTOR IIA; HEPARIN PLATELET FACTOR 4 ANTIBODY; LIPOCORTIN 5; PROCOAGULANT; PROTEIN KINASE SYK; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; ANTICOAGULANT AGENT; FC RECEPTOR; HEPARIN;

ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; FIBRIN DEPOSITION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROFLUIDICS; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; TRANSACTIVATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; COMPLICATION; IMMUNOLOGY; MICROFLUIDIC ANALYSIS; THROMBOCYTOPENIA;

ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; CELLS, CULTURED; HEPARIN; HUMANS; MICE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MONOCYTES; PLATELET ACTIVATION; PLATELET FACTOR 4; RECEPTORS, IGG; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84958093857     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-539262     Document Type: Article

References (44)

1. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68(1):95-96.
2. Sachais BS, Litvinov RI, Yarovoi SV, et al. Dynamic antibody-binding properties in the pathogenesis of HIT. Blood. 2012;120(5):1137-1142.
3. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507.
4. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparininduced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-135.
5. Warkentin TE, Sheppard JA, Heels-Ansdell D, et al; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest. 2013;144(3):848-858.
6. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-851.
7. Chong BH, Castaldi PA, Berndt MC. Heparininduced thrombocytopenia: effects of rabbit IgG, and its Fab and FC fragments on antibodyheparinplatelet interaction. Thromb Res. 1989;55(2):291-295.
8. Kelton JG, Sheridan D, Santos A, et al. Heparininduced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925-930.
9. Arepally G, Cines DB. Pathogenesis of heparininduced thrombocytopenia and thrombosis. Autoimmun Rev. 2002;1(3):125-132.
10. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353.
11. Rauova L, Hirsch JD, Greene TK, et al. Monocytebound PF4 in the pathogenesis of heparininduced thrombocytopenia. Blood. 2010;116(23):5021-5031.
12. Nader HB. Characterization of a heparan sulfate and a peculiar chondroitin 4-sulfate proteoglycan from platelets. Inhibition of the aggregation process by platelet chondroitin sulfate proteoglycan. J Biol Chem. 1991;266(16):10518-10523.
13. Ward JV, Packham MA. Characterization of the sulfated glycosaminoglycan on the surface and in the storage granules of rabbit platelets. Biochim Biophys Acta. 1979;583(2):196-207.
14. den Dekker E, Grefte S, Huijs T, et al. Monocyte cell surface glycosaminoglycans positively modulate IL-4-induced differentiation toward dendritic cells. J Immunol. 2008;180(6):3680-3688.
15. Wegrowski Y, Milard AL, Kotlarz G, Toulmonde E, Maquart FX, Bernard J. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Clin Exp Immunol. 2006;144(3):485-493.
16. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80(2):292-297.
17. Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem. 2010;285(37):28596-28603.
18. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95(5):1533-1540.
19. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642-2650.
20. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104(6):648-654.
21. Kirchhofer D, Moran P, Bullens S, Peale F, Bunting S. A monoclonal antibody that inhibits mouse tissue factor function. J Thromb Haemost. 2005;3(5):1098-1099.
22. Eslin DE, Zhang C, Samuels KJ, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood. 2004;104(10):3173-3180.
23. Reilly MP, Sinha U, André P, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011;117(7):2241-2246.
24. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
25. Conant CG, Nevill JT, Zhou Z, Dong JF, Schwartz MA, Ionescu-Zanetti C. Using well-plate microfluidic devices to conduct shear-based thrombosis assays. J Lab Autom. 2011;16(2):148-152.
26. George JN, Onofre AR. Human platelet surface binding of endogenous secreted factor VIII-von Willebrand factor and platelet factor 4. Blood. 1982;59(1):194-197.
27. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999;282(21):2035-2042.
28. Reilly MP, Taylor SM, Hartman NK, et al. Heparininduced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
29. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998;91(3):916-922.
30. Reilly MP, McKenzie SE. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol. 2002;9(5):395-400.
31. Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgRI. Blood. 2012;119(22):5285-5293.
32. Däeron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203-234.
33. Dougherty GJ, Selvendran Y, Murdoch S, Palmer DG, Hogg N. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. Eur J Immunol. 1987;17(10):1453-1459.
34. Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abraham GN, Anderson CL. Human platelet Fc receptor for immunoglobulin G. Identification as a 40, 000-molecular-weight membrane protein shared by monocytes. J Clin Invest. 1985;76(6):2317-2322.
35. Tamm A, Schmidt RE. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol. 1996;157(4):1576-1581.
36. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98(4):1252-1254.
37. Lyon ME, Fine JS, Henderson PJ, Lyon AW. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK): alternative anticoagulant to heparin salts for blood gas and electrolyte specimens. Clin Chem. 1995;41(7):1038-1041.
38. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6):879-887.
39. Batar P, Dale GL. Simultaneous engagement of thrombin and Fc gamma RIIA receptors results in platelets expressing high levels of procoagulant proteins. J Lab Clin Med. 2001;138(6):393-402.
40. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179.
41. Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol. 2013;161(5):706-714.
42. Xiao Z, Visentin GP, Dayananda KM, Neelamegham S. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood. 2008;112(4):1091-1100.
43. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316(10):581-589.
44. Kelton JG, Hursting MJ, Heddle N, Lewis BE. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul Fibrinolysis. 2008;19(6):471-475.